Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from EXAS

Exact Sciences Raises Fourth-Quarter Estimates Above Expectations

EXAS stock jumped as the provider of cancer screening and diagnostic tests raised estimates for its fourth quarter.

Investors Business Daily

Exact Sciences Rockets As Guardant's Blood Test Pales Vs. Cologuard

Exact Sciences Rockets As Guardant's Blood Test Pales Vs. Cologuard

Guardant unveiled results for its colon cancer-detecting blood test that lagged rival Exact. GH stock crashed as EXAS stock jumped Friday.

Investors Business Daily

Exact Sciences Surges After Massively Beating Quarterly Forecasts, Raising Outlook

Exact Sciences Surges After Massively Beating Quarterly Forecasts, Raising Outlook

Exact Sciences massively beat third-quarter expectations and raised its full-year outlook — and EXAS stock skyrocketed on Friday.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Exact Sciences's Return On Capital Employed Insights

According to data from Benzinga Pro, during Q1, Exact Sciences's (NASDAQ:EXAS) reported sales totaled $486.57 million. Despite a 17.98% increase in earnings, the company posted a loss of $180.94 million.

Here's How Much You Would Have Made Owning Exact Sciences Stock In The Last 10 Years

Exact Sciences (NASDAQ:EXAS) has outperformed the market over the past 10 years by 7.98% on an annualized basis producing an average annual return of 19.54%. Currently, Exact Sciences has a market capitalization of $10.72 billion.

Non-COVID Sales Boost Exact Sciences' Q1 Revenue; Revises FY22 Guidance

Exact Sciences Corp's (NASDAQ:EXAS) Q1 revenues increased 21% Y/Y to $486.6 million, beating the average Wall Street estimate of $461.71 million. Excluding COVID-19 testing revenues, which dropped 15% to $27.4 million, Exact's Q1 revenue increased 24%. Screening revenues rose 28% to $306.5 million in Q1, while Precision Oncology revenues were up 18%…

Analyst Ratings for Exact Sciences

Within the last quarter, Exact Sciences (NASDAQ:EXAS) has observed the following analyst ratings:

inkl

Read news from The Economist, FT, and more,
with one subscription

Here's How Much $1000 Invested In Exact Sciences 20 Years Ago Would Be Worth Today

Here's How Much $1000 Invested In Exact Sciences 20 Years Ago Would Be Worth Today

Exact Sciences (NASDAQ:EXAS) has outperformed the market over the past 20 years by 2.83% on an annualized basis producing an average annual return of 10.04%. Currently, Exact Sciences has a market capitalization of $11.93 billion.

3 Healthtech Stocks Wall Street Predicts Will Rally More Than 40% or More: GoodRx, 23andMe, and Exact Sciences

3 Healthtech Stocks Wall Street Predicts Will Rally More Than 40% or More: GoodRx, 23andMe, and Exact Sciences

The COVID-19 pandemic has accelerated digital adoption in healthcare. And because this trend is attracting massive investments into digital health care, Wall Street analysts expect popular health tech stocks Exact Sciences Corp (EXAS), GoodRx Holdings (GDRX), 23andMe (ME) to rally in price soon. Read on.

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much

Exact Sciences (NASDAQ:EXAS) has outperformed the market over the past 5 years by 12.08% on an annualized basis.

5 Cathie Wood Stocks Wall Street Predicts Will Rally 76% to 99%

5 Cathie Wood Stocks Wall Street Predicts Will Rally 76% to 99%

Renowned institutional investor Cathie Wood of Ark Investments fame is known for her market-beating investment strategies. Ark’s portfolio companies are attractive investments due to their long-term high growth potential and ability to withstand the current industry headwinds. Thus, Wall Street analysts expect fundamentally solid Cathie Wood stocks Coinbase (COIN), Zoom…

Where Exact Sciences Stands With Analysts

Where Exact Sciences Stands With Analysts

Over the past 3 months, 4 analysts have published their opinion on Exact Sciences (NASDAQ:EXAS) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Exact Sciences Clocks 16% Jump In Q4 Non-COVID-19 Revenues

Exact Sciences Clocks 16% Jump In Q4 Non-COVID-19 Revenues

Exact Sciences Corp's (NASDAQ: EXAS) Q4 revenues increas

3 Large-Cap Healthcare Stocks with More Than 40% Upside, According to Wall Street

3 Large-Cap Healthcare Stocks with More Than 40% Upside, According to Wall Street

The healthcare industry is growing rapidly on increasing demand and continuing advancements in therapies. Furthermore, this year is expected to be a transformative one for the healthcare sector, with a more robust transition to digital health. Given the industry's growth potential, Wall Street analysts see more than 40% potential upside…

Get all your
news in one place.

100’s of premium titles.
One news app.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

GoodRx Holdings Inc

Guardant Health

23andMe Holding Co

Exact Sciences Corporation

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

174,767 stories

Places

371,471 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play